Literature DB >> 9261430

Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase.

D J Hazuda1, P J Felock, J C Hastings, B Pramanik, A L Wolfe.   

Abstract

Previous in vitro analyses have shown that the human immunodeficiency virus type 1 (HIV-1) integrase uses either manganese or magnesium to assemble as a stable complex on the donor substrate and to catalyze strand transfer. We now demonstrate that subsequent to assembly, catalysis of both 3' end processing and strand transfer requires a divalent cation cofactor and that the divalent cation requirements for assembly and catalysis can be functionally distinguished based on the ability to utilize calcium and cobalt, respectively. The different divalent cation requirements manifest by these processes are exploited to uncouple assembly and catalysis, thus staging the reaction. Staged 3' end processing and strand transfer assays are then used in conjunction with exonuclease III protection analysis to investigate the effects of integrase inhibitors on each step in the reaction. Analysis of a series of related inhibitors demonstrates that these types of compounds affect assembly and not either catalytic process, therefore reconciling the apparent disparate results obtained for such inhibitors in assays using isolated preintegration complexes. These studies provide evidence for a distinct role of the divalent cation cofactor in assembly and catalysis and have implications for both the identification and characterization of integrase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261430      PMCID: PMC191986     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.

Authors:  K Raghavan; J K Buolamwini; M R Fesen; Y Pommier; K W Kohn; J N Weinstein
Journal:  J Med Chem       Date:  1995-03-17       Impact factor: 7.446

2.  Characterization of Mg(2+)-dependent 3'-processing activity for human immunodeficiency virus type 1 integrase in vitro: real-time kinetic studies using fluorescence resonance energy transfer.

Authors:  S P Lee; H G Kim; M L Censullo; M K Han
Journal:  Biochemistry       Date:  1995-08-15       Impact factor: 3.162

3.  Nucleotide binding by the HIV-1 integrase protein in vitro.

Authors:  J R Lipford; S T Worland; C M Farnet
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-12

4.  Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA.

Authors:  C Vink; R A Lutzke; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

5.  Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase.

Authors:  A Mazumder; A Gazit; A Levitzki; M Nicklaus; J Yung; G Kohlhagen; Y Pommier
Journal:  Biochemistry       Date:  1995-11-21       Impact factor: 3.162

6.  Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase.

Authors:  M Cushman; W M Golebiewski; Y Pommier; A Mazumder; D Reymen; E De Clercq; L Graham; W G Rice
Journal:  J Med Chem       Date:  1995-02-03       Impact factor: 7.446

7.  Inhibition of human immunodeficiency virus integrase by bis-catechols.

Authors:  R L LaFemina; P L Graham; K LeGrow; J C Hastings; A Wolfe; S D Young; E A Emini; D J Hazuda
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

8.  Inhibition of human immunodeficiency virus type 1 integrase by a hydrophobic cation: the phenanthroline-cuprous complex.

Authors:  A Mazumder; M Gupta; D M Perrin; D S Sigman; M Rabinovitz; Y Pommier
Journal:  AIDS Res Hum Retroviruses       Date:  1995-01       Impact factor: 2.205

9.  Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity.

Authors:  A Engelman; R Craigie
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Inhibition of human immunodeficiency virus type-1 integrase by curcumin.

Authors:  A Mazumder; K Raghavan; J Weinstein; K W Kohn; Y Pommier
Journal:  Biochem Pharmacol       Date:  1995-04-18       Impact factor: 5.858

View more
  23 in total

1.  Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation.

Authors:  Y Hwang; D Rhodes; F Bushman
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

Review 2.  Allosteric inhibitor development targeting HIV-1 integrase.

Authors:  Laith Q Al-Mawsawi; Nouri Neamati
Journal:  ChemMedChem       Date:  2011-01-12       Impact factor: 3.466

3.  A high-throughput assay for Tn5 Tnp-induced DNA cleavage.

Authors:  Brandon Ason; William S Reznikoff
Journal:  Nucleic Acids Res       Date:  2004-06-16       Impact factor: 16.971

4.  Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/M154I catalytic domain.

Authors:  Alessandro Brigo; Keun Woo Lee; Gabriela Iurcu Mustata; James M Briggs
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

5.  Discovery of a small-molecule HIV-1 integrase inhibitor-binding site.

Authors:  Laith Q Al-Mawsawi; Valery Fikkert; Raveendra Dayam; Myriam Witvrouw; Terrence R Burke; Christoph H Borchers; Nouri Neamati
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

6.  Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA.

Authors:  Gang Ren; Kui Gao; Frederic D Bushman; Mark Yeager
Journal:  J Mol Biol       Date:  2006-11-11       Impact factor: 5.469

Review 7.  Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors:  Alan N Engelman
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

Review 8.  Retroviral integrase proteins and HIV-1 DNA integration.

Authors:  Lavanya Krishnan; Alan Engelman
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

9.  A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Authors:  Daria J Hazuda; Neville J Anthony; Robert P Gomez; Samson M Jolly; John S Wai; Linghang Zhuang; Thorsten E Fisher; Mark Embrey; James P Guare; Melissa S Egbertson; Joseph P Vacca; Joel R Huff; Peter J Felock; Marc V Witmer; Kara A Stillmock; Robert Danovich; Jay Grobler; Michael D Miller; Amy S Espeseth; Lixia Jin; I-Wu Chen; Jiunn H Lin; Kelem Kassahun; Joan D Ellis; Bradley K Wong; Wei Xu; Paul G Pearson; William A Schleif; Riccardo Cortese; Emilio Emini; Vincenzo Summa; M Katharine Holloway; Steven D Young
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

10.  Mechanistic and pharmacological analyses of HIV-1 integration.

Authors:  Alan Engelman
Journal:  Methods       Date:  2009-04       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.